---
title: "enVVeno Medical | 10-Q: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285477200.md"
datetime: "2026-05-07T03:13:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285477200.md)
  - [en](https://longbridge.com/en/news/285477200.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285477200.md)
generator: "portal-rs"
---

# enVVeno Medical | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -5.89.

EBIT: As of FY2026 Q1, the actual value is USD -4.084 M.

enVVeno Medical Corporation operates in a single segment: Medical Device development in the United States. 

#### Operational Metrics (for the three months ended March 31)

-   **Net Loss**:
    -   Net loss was - $3.8 million in 2026, compared to - $4.5 million in 2025.
    -   This represents a decrease in net loss of $0.7 million, or 15%, primarily due to a $0.9 million decrease in operating expenses, partially offset by a $0.2 million decrease in other income.
-   **Loss from Operations**:
    -   Loss from operations was - $4.062 million in 2026, compared to - $4.954 million in 2025.
-   **Research and Development (R&D) Expenses**:
    -   R&D expenses were - $2.1 million in 2026, compared to - $2.6 million in 2025.
    -   This decreased by $0.5 million, or 17%, primarily due to $0.7 million lower costs related to the VenoValve pivotal study and a net decrease of $0.2 million in other expenses.
    -   This decrease was partially offset by a $0.4 million increase in product development, testing, and other expenses for the enVVe System.
    -   **Detailed R&D Expenses**:
        -   Employee expense: $1,136 thousand in 2026 vs. $1,369 thousand in 2025.
        -   Clinical: $844 thousand in 2026 vs. $872 thousand in 2025.
        -   Product: $78 thousand in 2026 vs. $146 thousand in 2025.
        -   Other R&D: $53 thousand in 2026 vs. $170 thousand in 2025.
-   **Selling, General and Administrative (SG&A) Expenses**:
    -   SG&A expenses were - $2.0 million in 2026, compared to - $2.4 million in 2025.
    -   This decreased by $0.4 million, or 19%, due to lower stock-based compensation costs and a net decrease in various other expenses.
    -   **Detailed SG&A Expenses**:
        -   Employee expense: $1,063 thousand in 2026 vs. $1,234 thousand in 2025.
        -   Professional fees: $386 thousand in 2026 vs. $580 thousand in 2025.
        -   Occupancy: $161 thousand in 2026 vs. $164 thousand in 2025.
        -   Insurance: $144 thousand in 2026 vs. $163 thousand in 2025.
        -   Other SG&A: $197 thousand in 2026 vs. $256 thousand in 2025.
-   **Other Income**:
    -   Other income was $0.2 million in 2026, compared to $0.5 million in 2025.
    -   This decreased by $0.3 million, or 53%, and consisted of realized gains, interest, and unrealized gains or losses from investments in U.S. Treasury securities.

#### Cash Flow and Liquidity

-   **Net Cash Used in Operating Activities**:
    -   Net cash used in operating activities was - $3.2 million in 2026, compared to - $4.0 million in 2025.
    -   The $0.8 million decrease in cash used was primarily due to the decrease in R&D expenses.
-   **Cash and Investments Balance**:
    -   As of March 31, 2026, cash and investments totaled $24.9 million, comprising $2.6 million in cash and $22.3 million in investments.
    -   This compares to $28.2 million as of December 31, 2025.
-   **Working Capital**:
    -   Working capital was $23.3 million as of March 31, 2026.
-   **Capital Raised (Subsequent Event in April 2026)**:
    -   Approximately $0.1 million net was raised through an at-the-market equity offering of 12,148 shares of common stock.
    -   An additional approximately $48.8 million of common stock may be sold under the at-the-market equity program.

#### Future Outlook and Strategy

enVVeno Medical Corporation expects to continue incurring losses and anticipates its quarterly cash burn rate to increase from $3-$4 million to $4-$5 million in 2026. Despite this, the company believes its current cash and investments are sufficient to fund operations into the third quarter of 2027 and meet obligations within one year, though additional capital will be needed in the future. The company’s strategic focus has shifted to the non-surgical enVVe System, with the FDA approving the Investigational Device Exemption (IDE) application for the Transcatheter Venous Valve Endoprosthesis (TAVVE) pivotal study, which will evaluate the system in two stages.

### Related Stocks

- [NVNO.US](https://longbridge.com/en/quote/NVNO.US.md)

## Related News & Research

- [enVVeno Medical wins FDA IDE approval for enVVe pivotal trial in deep venous insufficiency](https://longbridge.com/en/news/297191037.md)
- [ENvue Medical announces 1-for-12 reverse stock split effective Sept. 1](https://longbridge.com/en/news/297321134.md)
- [ENvue Medical announces 1-for-12 reverse stock split](https://longbridge.com/en/news/297559591.md)
- [Xenon CMO Christopher John Kenney reports disposal of common shares worth $425,469.33](https://longbridge.com/en/news/297582920.md)
- [Tenon Medical completes $3M private warrant financing](https://longbridge.com/en/news/297555992.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**